Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy:: A review

被引:15
作者
Walker, PD
Brokering, KL
Theobald, JC
机构
[1] St Louis Coll Pharm, Div Pharm Practice, St Louis, MO 63110 USA
[2] St Elizabeth Hosp, Dept Pharm, Belleville, IL USA
[3] Univ Alabama, Sch Med, Tuscaloosa, AL 35401 USA
[4] Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA
来源
PHARMACOTHERAPY | 2003年 / 23卷 / 12期
关键词
fenoldopam; N-acetylcysteine; nephropathy; radiographic contrast;
D O I
10.1592/phco.23.15.1617.31958
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Radiographic contrast material-induced nephropathy (RCIN) is the third most common cause of hospital-acquired renal insufficiency and has been associated with an increase in patient mortality Many strategies to prevent RCIN have been explored unsuccessfully. The standard of care remains hydration with 0.45% sodium chloride before and after administration of contrast material. Recently, N-acetylcysteine and fenoldopam have been studied to determine their efficacy in preventing RCIN. Of seven prospective studies using various dosing regimens of N-acetylcysteine, four revealed beneficial results. Although some discrepancies exist, the data strongly suggest that N-acetylcysteine has a role in patients at risk for the development of RCIN. The data for fenoldopam are more limited, with only one retrospective study showing benefit. Additional prospective data are required to determine if fenoldopam has a role in the prevention of RCIN.
引用
收藏
页码:1617 / 1626
页数:10
相关论文
共 26 条
[1]  
Adamian MG, 2002, J AM COLL CARDIOL, V39, p1A
[2]   Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy [J].
Allaqaband, S ;
Tumuluri, R ;
Malik, AM ;
Gupta, A ;
Volkert, P ;
Shalev, Y ;
Bajwa, TK .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2002, 57 (03) :279-283
[3]   RADIOCONTRAST MEDIUM-INDUCED DECLINES IN RENAL-FUNCTION - A ROLE FOR OXYGEN FREE-RADICALS [J].
BAKRIS, GL ;
LASS, N ;
GABER, AO ;
JONES, JD ;
BURNETT, JC .
AMERICAN JOURNAL OF PHYSIOLOGY, 1990, 258 (01) :F115-F120
[4]   MECHANISMS OF DISEASE - HYPOXIA OF THE RENAL MEDULLA - ITS IMPLICATIONS FOR DISEASE [J].
BREZIS, M ;
ROSEN, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (10) :647-655
[5]   Acetylcysteine and contrast agent-associated nephrotoxicity [J].
Briguori, C ;
Manganelli, F ;
Scarpato, P ;
Elia, PP ;
Golia, B ;
Riviezzo, G ;
Lepore, S ;
Librera, M ;
Villari, B ;
Colombo, A ;
Ricciardelli, B .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (02) :298-303
[6]  
Brophy DF, 2002, ANN PHARMACOTHER, V36, P1466
[7]   Using a dopamine type 1A receptor-agonist in high-risk patients to ameliorate contrast-associated nephropathy [J].
Chamsuddin, AA ;
Kowalik, KJ ;
Bjarnason, H ;
Dietz, CA ;
Rosenberg, MS ;
Gomes, MD ;
McDermott, CM ;
Hunter, DW .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2002, 179 (03) :591-596
[8]  
Chu VL, 2001, ANN PHARMACOTHER, V35, P1278
[9]   Acetylcysteine to prevent angiography-related renal tissue injury (the APART Trial) [J].
Diaz-Sandoval, LJ ;
Kosowsky, BD ;
Losordo, DW .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (03) :356-+
[10]   A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography [J].
Durham, JD ;
Caputo, C ;
Dokko, J ;
Zaharakis, T ;
Pahlavan, M ;
Keltz, J ;
Dutka, P ;
Marzo, K ;
Maesaka, JK ;
Fishbane, S .
KIDNEY INTERNATIONAL, 2002, 62 (06) :2202-2207